Cyclacel Pharmaceuticals, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.
The company announced in the following Press release that, “In two animal models of NSCLC the combination of seliciclib and erlotinib was more effective in suppressing tumor growth than either drug alone.”
Cyclacel Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders. Its lead candidate, sapacitabine, oral nucleoside analogue prodrug that acts through a novel mechanism. It also develops Seliciclib and CYC065-Second Generation CDK Inhibitor. The company was founded by Ronald J. Berenson, David Philip Lane and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ. [Source: MarketWatch]
Company Website: http://www.cyclacel.com